GB00B128J450) Rises on Strong 2025 Earnings and Strategic Par

Hikma Pharmaceuticals PLC stock (ISIN: GB00B128J450), the London-listed generic drug maker, is gaining traction today following the release of its 2025 Annual Report highlighting a 12% rise in full-year net profit to $402 million, or $1.81 per share, from $359 million the prior year. Revenue climbed 7.1% to $3.34 billion, driven by growth across injectable and oral generics segments, with adjusted earnings reaching $503 million or $2.26 per share. This performance underscores Hikma’s resilience in a volatile market, positioning it as a defensive pick for European investors amid broader FTSE uncertainty.

As of: 18.03.2026

By Dr. Elena Voss, Senior Pharma Equity Analyst – ‘Tracking generic drug innovators bridging US and MENA markets for sustainable European portfolios.’

Market Reaction to 2025 Results

Hikma’s shares traded at 1,281 GBX early today, down 0.54% intraday but up 5.35% over five days after yesterday’s 1.5% gain on healthcare demand. The FTSE 100 healthcare sector is attracting value investors as tech falters, with Hikma’s cash-generative model shining. For DACH investors, the stock’s Xetra availability offers euro-denominated exposure to US generics growth without direct currency risk.

Core Financial Highlights and Segment Drivers

Injectables, comprising 41.8% of sales, led growth alongside oral generics at 32.8%, with branded drugs at 24.7%. US sales dominate at 61.1%, MENA at 31.5%, providing geographic balance against regional headwinds. Adjusted metrics reflect operational leverage, with management emphasizing 2026 as a focus year for execution. European investors value this stability, especially as DAX pharma peers face pricing pressures.

Strategic Partnerships Fuel US and MENA Expansion

The 2025 report spotlights partnerships accelerating regulatory approvals and market access, optimizing capital with shared risk. Executive VP Bassam Kanaan noted these deals complement Hikma’s infrastructure, targeting portfolio growth. In MENA, investments expand affordable medicine access, aligning with regional healthcare budgets. For Swiss and German funds, this de-risks exposure to emerging markets versus pure-play US generics.

Business Model: Generics Powerhouse with Branded Upside

Hikma operates as a global generics leader, focusing on hospital injectables for infections, oncology, and cardiology, plus oral solids and branded MENA products. Unlike big pharma innovators, its model thrives on volume, pricing stability post-patent cliffs, and supply chain efficiency. 9,300 employees drive this, with venture capital arm fostering innovations. European investors appreciate the low R&D burn versus sector peers, enabling reliable dividends.

DACH and European Investor Perspective

On Xetra, Hikma offers DACH portfolios a liquid FTSE 100 pharma holding amid ECB rate caution. Recent FTSE reshuffle saw Hikma dropped from the index on March 5, but earnings beat cushions impact, unlike easyJet. German value managers favor its 61% US revenue for dollar strength against euro, while MENA ties hedge oil volatility affecting Gulf funds. Austrian and Swiss investors eye defensive traits as Stoxx Europe 600 pharma lags broader markets.

Analyst Views and Valuation Setup

11 analysts rate Hikma a Buy, with average target implying 47.78% upside from $17.19 close equivalent. Quality and value composites support this, though February outlook concerns linger. Dividend appeal grows as a ‘hidden gem’ in healthcare, per recent analysis. Chart shows support near 50-day SMA, with momentum building post-earnings.

Cash Flow, Dividends, and Capital Allocation

Strong adjusted profits bolster free cash flow for dividends, buybacks, and M&A. Balance sheet strength (BBB ratings) supports 2026 priorities like partnership scaling. Trade-off: capex for capacity versus payouts, but generics’ high conversion favors returns. European funds tracking yield prioritize this over growth multiples.

Risks and Catalysts Ahead

Risks include US pricing reforms, MENA geopolitical tensions, and generic competition eroding margins. FTSE relegation adds index fund outflows, though fundamentals offset. Catalysts: 2026 AGM outcomes, new launches from partnerships, Q1 trading update. Positive Hormuz dynamics could lift MENA sentiment. Outlook favors steady growth if execution holds.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.

Hol dir jetzt den Wissensvorsprung der Aktien-Profis.